Decompression of Axillary vein - An essential adjunct for advanced lymphedema.

INTRODUCTION: In advanced lymphedema, lymphovenous anastomosis (LVA) can be a solution based on utilizing the pressure gradient between the high pressure lymphatics and low pressure veins. If the vein pressure in high, the effect affect surgery will be less optimal. This study evaluated the effect of axillary vein perivascular scar release on LVA. MATERIALS AND METHODS: This is a retrospective study of 40 upper limb stage 2 and 3 lymphedema patients divided into 2 groups with an average follow-up of 33 months (minimal of at least 12 months); scar-released group (n=25) and control group (n=15). All patients underwent LVA with or without lymph node transfer. Demographic data, outcome (volumetric change and bioimpedence analysis (BIA)), and major veins (axillary, basilic and cephalic) diameter changes were evaluated. RESULTS: Both groups showed significant reduction in volume and BIA parameters after LVA. The scar-released groups (24/25 with lymph node transfer and 1 without) showed statistically higher reduction of BIA analysis compared to the control group at 1, 6 and 12 months after LVA. The changes in the major veins after axilla scar release showed significant changes in all 3 veins. There was a significant correlation between cephailic vein dimeter reduction and BIA measurement. CONCLUSION: The release of perivascular scar in the axially vein may result in better outcome after LVA. This is based on the finding that scar release shows correlation between cephailic vein dimeter reduction and BIA measurement suggesting reduction of venous pressure in the peripheral vein increasing the pressure gradient between the lymphatic and venous system allowing better outflow after LVA.

Outcomes of smooth round implant-based immediate breast reconstruction: Long-term follow-up results.

The issue of breast implant-associated anaplastic large cell lymphoma in 2019 has resulted in the discontinuation of textured breast implants and resumption in the use of smooth round implants. However, in the field of breast reconstruction, long-term follow-up data for direct-to-implant reconstruction using smooth round implants is insufficient. This retrospective study aimed to evaluate the long-term outcomes of breast reconstruction using smooth round implants. This study included 185 patients (208 breasts) who underwent smooth round implant-based immediate breast reconstruction between 2007 and 2018. Their demographic information and surgical and oncological data were collected. Early (within 90 days) and late (after 90 days) complications, reoperations, implant maintenance, and the survival rate were analyzed to evaluate the long-term outcomes and identify the related factors. The mean follow-up period was 112.08 months. The most common early complications were skin necrosis (9.13%) and infection (3.85%). The factors influencing the development of early complications were the mastectomy specimen weight (237.14 ± 114.84 cc and 298.04 ± 141.53 cc for no complication and any complication, respectively; p = 0.0123) and implant volume (222.79 ± 77.76 cc and 264.48 ± 89.03 cc for no complication and any complication, respectively; p = 0.0082). The most common late complication was capsular contracture (13.46%). Approximately 91.35% of the implants were maintained during the follow-up period. The factors affecting the development of early complications and implant maintenance were the mastectomy specimen weight and implant volume. This study provides information on long-term follow-up results useful in cases where only smooth round implants are available, which can then serve as a basis for future related studies.

Complications arising from clinical application of composite polycaprolactone/bioactive glass ceramic implants for craniofacial reconstruction: A prospective study.

This study aimed to demonstrate the in vitro performance of a novel polymer-ceramic composite incorporating polycaprolactone (PCL) and bioactive glass (BGS-7), and investigate its clinical outcomes in craniofacial reconstruction. After preparation of the material, the biochemical properties of the composite PCL/BGS-7 implant were tested to evaluate apatite formation in simulated body fluid (SBF). Changes in the implant surface after soaking in the SBF were determined using field-emission scanning electron microscopy. For clinical application of the implant, patients with craniofacial defects were prospectively enrolled to receive three-dimensional (3D)-printed PCL/BGS-7 implants. Clinical outcomes were investigated by reviewing postoperative complications, including wound problems, allergic responses, hematoma, seroma, implant displacement, and bone union. The accuracy of reconstruction was assessed by measuring the surface error between the reconstructed and mirrored models. Upon exposure of the PCL/BGS-7 implant to SBF, apatite particles were actively developed on the surface of the PCL/BGS-7 sample, showing favorable bone-binding capacity. Regarding the clinical application, seven patients with craniofacial defects were included. The clinical outcome was favorable in terms of complications, except in one patient, who presented with delayed wound healing due to previous irradiation. The patients showed improvements in symmetry, with a significant change in mean ± SD surface error between preoperative (5 ± 3 mm) and postoperative (1.5 ± 0.65 mm) status (p = 0.018). Wthin the limitations of the study it seems that the PCL/BGS-7 implants might be a relevant option for repairing craniofacial bone defects, owing to its favorable bone-binding property and clinical safety, with few complications.